
Mesoblast (NASDAQ:MESO) is preparing a regulatory filing for its cell therapy rexlemestrocel-L in a rare population of patients with end-stage heart failure, while awaiting pivotal trial results in chronic low back pain and advancing an adult study of its approved product RYONCIL.
Chief Executive Officer Silviu Itescu said the company reported fiscal 2026 net revenue of $115 million and gross profit, excluding amortization expenses, of $110 million. He said RYONCIL, approved for pediatric steroid-refractory graft-versus-host disease, had completed a successful first year on the market.
More than 50 treatment centers have been onboarded, and insurers covering more than 98% of commercially insured U.S. lives cover RYONCIL, Itescu said. He also said Mesoblast entered a $125 million, five-year credit facility that retired and consolidated two higher-cost facilities.
Back pain trial readout expected in 2027
Mesoblast has completed treatment of 350 patients in its second randomized Phase 3 trial of rexlemestrocel-L for chronic low back pain, Itescu said. The study is assessing whether a single injection into a spinal disc reduces pain compared with placebo over 12 months.
The primary endpoint is expected to be evaluated around mid-2027. Itescu said an earlier Phase 3 trial met the pain-reduction goal, and the current study is intended to confirm that result.
If the trial is positive, Mesoblast aims to file for approval by the end of 2027 or shortly thereafter, he said. The company is also working on commercial manufacturing for the product.
Heart failure filing strategy
Itescu said Mesoblast had aligned with the Food and Drug Administration on a potential filing for rexlemestrocel-L in patients with end-stage heart failure supported by a left ventricular assist device, or LVAD. He said a completed randomized trial showed a significant reduction in serious bleeding, an important complication for those patients.
The CEO said the company is weighing how much manufacturing information to include in an LVAD filing and how that package could support a later back pain application. He said an orphan indication could allow a more abbreviated manufacturing package than a broader, non-orphan indication.
Mesoblast is also studying the therapy’s potential in the broader heart failure population, including patients with pulmonary hypertension. In a subgroup of a heart failure trial, Itescu said, a single injection reduced cardiac deaths from right heart failure by 53%. He said the company had not yet discussed a pulmonary hypertension approval pathway with the FDA.
RYONCIL expansion
A randomized trial is underway to support extending RYONCIL’s label to adults with steroid-refractory graft-versus-host disease. Itescu said the adult market is approximately three to four times the size of the pediatric market Mesoblast is targeting.
The study could enroll up to 180 patients, with a potential early analysis after 100 patients. If results exceed the required threshold at that point, the company could stop the trial and seek a label extension; otherwise, it would continue enrollment, Itescu said.
He also cited an earlier expanded-access program in which approximately 53 adults who had largely failed second-line treatment had a survival outcome of about 76%. The FDA nonetheless requested a randomized controlled trial, he said.
Mesoblast also plans to begin a Phase 3 trial in Duchenne muscular dystrophy during 2027, following FDA clearance for the study, Itescu said.
About Mesoblast (NASDAQ:MESO)
Mesoblast is an Australia-based biotechnology company developing regenerative medicine products made from mesenchymal lineage cells. Its allogeneic cell therapies are designed to address inflammatory and immune-mediated conditions by modulating the body’s immune response and supporting tissue repair. The company’s lead commercial product, Ryoncil (remestemcel-L-rknd), is approved in the United States to treat steroid-refractory acute graft-versus-host disease in pediatric patients. A related product, marketed as Temcell in Japan, is used there to treat acute graft-versus-host disease.
